341 related articles for article (PubMed ID: 19172544)
21. Changes in tissue inflammation, angiogenesis and apoptosis in endometriosis, adenomyosis and uterine myoma after GnRH agonist therapy.
Khan KN; Kitajima M; Hiraki K; Fujishita A; Sekine I; Ishimaru T; Masuzaki H
Hum Reprod; 2010 Mar; 25(3):642-53. PubMed ID: 20008888
[TBL] [Abstract][Full Text] [Related]
22. An evaluation of the effect of gonadotropin-releasing hormone analogs and medroxyprogesterone acetate on uterine leiomyomata volume by magnetic resonance imaging: a prospective, randomized, double blind, placebo-controlled, crossover trial.
Carr BR; Marshburn PB; Weatherall PT; Bradshaw KD; Breslau NA; Byrd W; Roark M; Steinkampf MP
J Clin Endocrinol Metab; 1993 May; 76(5):1217-23. PubMed ID: 8496313
[TBL] [Abstract][Full Text] [Related]
23. The effect of anastrazole on symptomatic uterine leiomyomata.
Varelas FK; Papanicolaou AN; Vavatsi-Christaki N; Makedos GA; Vlassis GD
Obstet Gynecol; 2007 Sep; 110(3):643-9. PubMed ID: 17766612
[TBL] [Abstract][Full Text] [Related]
24. Vaginal expulsion of a submucosal myoma during treatment with long-acting gonadotropin-releasing hormone agonist.
Wen L; Tseng JY; Wang PH
Taiwan J Obstet Gynecol; 2006 Jun; 45(2):173-5. PubMed ID: 17197363
[TBL] [Abstract][Full Text] [Related]
25. [Surgical treatment of subserosal fibroids: the cons].
Marret H; Ouldamer L
Gynecol Obstet Fertil; 2011; 39(7-8):454-7. PubMed ID: 21752689
[No Abstract] [Full Text] [Related]
26. [Use of GnGH (GnRH-A) in gynecology].
Ciardo A; Spina V; Aleandri V
Minerva Ginecol; 1998; 50(1-2):25-9. PubMed ID: 9577152
[TBL] [Abstract][Full Text] [Related]
27. Changes in insulin sensitivity during GnRH agonist treatment in premenopausal women with leiomyoma.
Matsui S; Yasui T; Tani A; Kunimi K; Uemura H; Yamamoto S; Kuwahara A; Matsuzaki T; Tsuchiya N; Yuzurihara M; Kase Y; Irahara M
Clin Chim Acta; 2012 Jun; 413(11-12):960-5. PubMed ID: 22366120
[TBL] [Abstract][Full Text] [Related]
28. Pathological evaluation of uterine leiomyomas treated with gonadotropin-releasing hormone agonist (GnRH-a) therapy: role of mast cells and a possible mechanism of GnRH-a resistance in leiomyomas.
Nakayama M; Mitsuhashi T; Shimizu Y; Ishihara O; Shimizu M
Pathol Int; 2008 May; 58(5):268-74. PubMed ID: 18429824
[TBL] [Abstract][Full Text] [Related]
29. The GnRH agonists in the treatment of uterine leiomyomas.
Bianchi S; Fedele L
Acta Eur Fertil; 1989; 20(1):5-10. PubMed ID: 2675524
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of tibolone as "add-back therapy" in conjunction with a gonadotropin-releasing hormone analogue in the treatment of uterine fibroids.
Morris EP; Rymer J; Robinson J; Fogelman I
Fertil Steril; 2008 Feb; 89(2):421-8. PubMed ID: 17572410
[TBL] [Abstract][Full Text] [Related]
31. [GnRH agonists and antagonists in the preoperative therapy of uterine fibroids: literature review].
De Falco M; Pollio F; Pontillo M; Ambrosino E; Busiello A; Carbone IF; Ciociola F; Di Nardo MA; Landi L; Di Lieto A
Minerva Ginecol; 2006 Dec; 58(6):553-60. PubMed ID: 17108883
[TBL] [Abstract][Full Text] [Related]
32. Treatment of leiomyomata with intranasal or subcutaneous leuprolide, a gonadotropin-releasing hormone agonist.
Friedman AJ; Barbieri RL; Benacerraf BR; Schiff I
Fertil Steril; 1987 Oct; 48(4):560-4. PubMed ID: 3115833
[TBL] [Abstract][Full Text] [Related]
33. Pregnancy outcomes after uterine artery occlusion: prospective multicentric study.
Holub Z; Mara M; Kuzel D; Jabor A; Maskova J; Eim J
Fertil Steril; 2008 Nov; 90(5):1886-91. PubMed ID: 18155701
[TBL] [Abstract][Full Text] [Related]
34. Serum vascular endothelial growth factor165 levels and uterine fibroid volume.
Chen DC; Liu JY; Wu GJ; Ku CH; Su HY; Chen CH
Acta Obstet Gynecol Scand; 2005 Apr; 84(4):317-21. PubMed ID: 15762959
[TBL] [Abstract][Full Text] [Related]
35. What is the place of uterine artery embolisation in the management of symptomatic uterine fibroids?
Hickey M; Hammond I
Aust N Z J Obstet Gynaecol; 2008 Aug; 48(4):360-8. PubMed ID: 18837841
[TBL] [Abstract][Full Text] [Related]
36. Clinical response, vascular change, and angiogenesis in gonadotropin-releasing hormone analogue-treated women with uterine myomas.
Di Lieto A; De Falco M; Pollio F; Mansueto G; Salvatore G; Somma P; Ciociola F; De Rosa G; Staibano S
J Soc Gynecol Investig; 2005 Feb; 12(2):123-8. PubMed ID: 15695108
[TBL] [Abstract][Full Text] [Related]
37. Combined differential gene expression profile and pathway enrichment analyses to elucidate the molecular mechanisms of uterine leiomyoma after gonadotropin-releasing hormone treatment.
Chen HW; Liu JC; Chen JJ; Lee YM; Hwang JL; Tzeng CR
Fertil Steril; 2008 Oct; 90(4):1219-25. PubMed ID: 18258233
[TBL] [Abstract][Full Text] [Related]
38. Morphometric and electron-microscopic analyses of the effects of gonadotropin-releasing hormone agonists on uterine leiomyomas.
Kalir T; Goldstein M; Dottino P; Brodman M; Gordon R; Deligdisch L; Wu H; Gil J
Arch Pathol Lab Med; 1998 May; 122(5):442-6. PubMed ID: 9593346
[TBL] [Abstract][Full Text] [Related]
39. Sexual functioning and psychological well-being after uterine artery embolization in women with symptomatic uterine fibroids.
Voogt MJ; De Vries J; Fonteijn W; Lohle PN; Boekkooi PF
Fertil Steril; 2009 Aug; 92(2):756-61. PubMed ID: 18692808
[TBL] [Abstract][Full Text] [Related]
40. [Gonadotropin-releasing hormone analogs].
Krysiak R; Okopień B; Herman ZS
Pol Merkur Lekarski; 2005 May; 18(107):585-9. PubMed ID: 16161962
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
